Latest Transposon Therapeutics News & Updates
See the latest news and media coverage for Transposon Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of reverse transcriptase inhibitors for neurodegenerative diseases
transposonrx.com- Headquarters
- San Diego, United States
- Founded year
- 2020
- Company type
- Private company
- Number of employees
- 10–50
Latest news about Transposon Therapeutics
Company announcements
-
Transposon Therapeutics receives ARPA-H award for TPN-101
The up to $22M funding supports studying TPN-101 to extend healthspan under the PROSPR program. It targets LINE-1 inhibition to slow aging-related diseases.
-
Transposon receives ADDF investment for TPN-101 Alzheimer’s trial
Plans Phase 2 trial in Q4 2025, building on positive PSP and ALS results. Advances in HEALEY ALS trial.
-
Transposon Therapeutics announces TPN-101 inclusion
TPN-101 joins Phase 2/3 HEALEY ALS Platform Trial after promising Phase 2 results in C9orf72-related ALS.
-
Transposon Therapeutics presents Phase 2 results of TPN-101
Treatment shows clinical benefits on ALSFRS-R, SVC, and lowers NfL, IL-6 biomarkers at ALS/MND Symposium.
Media coverage
-
URochester researchers awarded up to $22M to study a hidden driver of aging
What if people could stay healthier, stronger, and mentally sharper as they grow older—not by treating diseases one by one but by slowing a biological...
-
Transposon Receives Investment From The Alzheimer's Drug Discovery Foundation To Support Advancement Of TPN-101 For The Treatment Of Alzheimer's Disease
Building on the positive results of Phase 2 clinical trials in PSP and ALS, Transposon plans to initiate a Phase 2 clinical trial of TPN-101...
-
Transposon Announces TPN-101 Selected for Inclusion in the Phase 2/3 HEALEY ALS Platform Trial, Building on the Success of Phase 2 Study in C9orf72-related ALS
News provided by Transposon Therapeutics May 28, 2025, 8:00 AM ET In the Phase 2 Study of TPN-101 in patients with C9orf72-related ALS, TPN-101 showed...
-
Transposon Therapeutics Strengthens and Expands Development Pipeline with the Acquisition of a Portfolio of Novel Nucleoside Analogs for Oncology
Builds upon leadership position in developing best-in-class, late-stage nucleoside reverse transcriptase inhibitors for neurodegenerative and autoimmune diseases SAN DIEGO, Nov. 21, 2024 /PRNewswire/ -- Transposon...
Track Transposon Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Transposon Therapeutics competitors & trending companies
Browse news for competitors to Transposon Therapeutics and other trending companies.
QurAlis
Acelot
AlzeCure Pharma
Vesalic
Verge Genomics
Harness Therapeutics
Aquilus Pharmaceuticals
Canurta Therapeutics
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore
BlueConic
Amperity
Wero
BLIK
EPI
Swish
Affirm
Brite Payments
TCS
Overview Energy
Adfin
Ineffable Intelligence
Mechanize
Hexatronic
Alimak Group